California State Teachers Retirement System Decreases Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

California State Teachers Retirement System decreased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 8.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,241,262 shares of the company's stock after selling 110,266 shares during the quarter. California State Teachers Retirement System owned about 0.11% of Teva Pharmaceutical Industries worth $27,357,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after acquiring an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $4,966,000. Asset Management One Co. Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock worth $23,368,000 after acquiring an additional 1,045,305 shares during the period. Finally, Capital Wealth Planning LLC grew its holdings in shares of Teva Pharmaceutical Industries by 8.8% in the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock worth $5,435,000 after acquiring an additional 20,016 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Bank of America upped their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $24.50.

Teva Pharmaceutical Industries Stock Down 4.3%

TEVA traded down $0.76 during midday trading on Friday, hitting $16.77. The company had a trading volume of 19,852,269 shares, compared to its average volume of 10,116,301. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock's 50 day moving average price is $15.52 and its 200 day moving average price is $17.36. The company has a market capitalization of $19.01 billion, a price-to-earnings ratio of -11.57, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same period in the previous year, the company earned $0.48 earnings per share. The company's quarterly revenue was up 1.9% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.